Life Biosciences has launched the first human clinical trial for its cellular reprogramming therapy, marking a pivotal moment in age-reversal research. The approach leverages modified Yamanaka factors—Oct4, Sox2, and Klf4—to reset cellular age without the cancer-risk factor c-Myc, building on Harvard researcher Yuancheng Lu's successful mouse trials.
The therapy's potential to regenerate damaged tissues could revolutionize medicine, though safety concerns linger. Dr. David Sinclair, Life Biosciences founder, highlighted the milestone on social media, signaling confidence in the technology's transition from lab to clinic.
Log in to Reply
Log in to comment your thoughtsComments